Oruka Therapeutics, Inc. (ORKA), Friday announced the preclinical data for ORKA-002, a novel extended half-life monoclonal antibody targeting IL-17A/F.
The findings, presented at the 2025 American Academy of Dermatology Annual Meeting, revealed that half-life in non-human primates of more than 30 days, is over three times longer than bimekizumab and expected to support a dose interval of two to three times per year.
The company further expects ORKA-002 to offer an even better product profile to people with psoriasis, psoriatic arthritis, and additional indications.
Oruka added that the first subject dosed with ORKA-002 is expected in the third quarter of 2025.
Currently, Oruka's stock is trading at $10.05, down 0.20 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.